- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly, Boehringer Ingelheim gets USFDA nod for Jardiance to treat heart failure regardless of ejection fraction
Indianapolis: Eli Lilly and Company and Boehringer Ingelheim have recently announced that the U.S. Food and Drug Administration (USFDA) has approved Jardiance (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization in adults with heart failure.Jardiance can be initiated in adults with heart failure with an eGFR as low as 20 mL/min/1.73 m2. "In its phase III...
Indianapolis: Eli Lilly and Company and Boehringer Ingelheim have recently announced that the U.S. Food and Drug Administration (USFDA) has approved Jardiance (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization in adults with heart failure.
Jardiance can be initiated in adults with heart failure with an eGFR as low as 20 mL/min/1.73 m2. "In its phase III trials, empagliflozin has shown a statistically significant and clinically meaningful benefit in patients with heart failure across the spectrum of ejection fraction," said Javed Butler, M.D., chairman, Department of Medicine, University of Mississippi. "The approval means these demonstrated benefits can now help to address a significant unmet need for the approximately 3 million adults in the U.S. with preserved ejection fraction, a form of heart failure that has very limited treatment options."
Jardiance can be initiated in adults with heart failure with an eGFR as low as 20 mL/min/1.73 m2.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.